Reproductive issues in carriers of germline pathogenic variants in the BRCA1/2 genes: an expert meeting

[1]  M. Ceppi,et al.  Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  F. Peccatori,et al.  Fertility preservation in endocrine responsive breast cancer: data and prejudices , 2020, Ecancermedicalscience.

[3]  M. Lambertini,et al.  Preimplantation genetic testing for carriers of BRCA1/2 pathogenic variants. , 2020, Critical reviews in oncology/hematology.

[4]  H. V. van Boven,et al.  Long-Term Risk of Ovarian Cancer and Borderline Tumors After Assisted Reproductive Technology. , 2020, Journal of the National Cancer Institute.

[5]  B. Kiely,et al.  5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) , 2020, Annals of Oncology.

[6]  F. Amant,et al.  Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  H. Tournaye,et al.  Live births following fertility preservation using in-vitro maturation of ovarian tissue oocytes. , 2020, Human reproduction.

[8]  K. Pogoda,et al.  Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Humaidan,et al.  Reproductive outcomes after in vitro fertilization treatment in a cohort of Danish women transplanted with cryopreserved ovarian tissue. , 2020, Fertility and sterility.

[10]  K. Phillips,et al.  The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation. , 2020, Human reproduction.

[11]  R. Manchanda,et al.  Population-based genetic testing for Women's cancer prevention. , 2020, Best practice & research. Clinical obstetrics & gynaecology.

[12]  E. Winer,et al.  TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Jing Qu,et al.  Fertility preservation in BRCA mutation carriers—efficacy and safety issues: a review , 2020, Reproductive biology and endocrinology : RB&E.

[14]  R. Andrés,et al.  SEOM clinical guidelines in hereditary breast and ovarian cancer (2019) , 2019, Clinical and Translational Oncology.

[15]  E. Porcu,et al.  Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer , 2019, Journal of Assisted Reproduction and Genetics.

[16]  V. Turan,et al.  BRCA-related ATM-mediated DNA double-strand break repair and ovarian aging. , 2019, Human reproduction update.

[17]  C. Lázaro,et al.  Assessment of ovarian reserve and reproductive outcomes in BRCA1 or BRCA2 mutation carriers , 2019, International Journal of Gynecological Cancer.

[18]  L. Louwé,et al.  Ovarian tissue cryopreservation: Low usage rates and high live‐birth rate after transplantation , 2019, Acta obstetricia et gynecologica Scandinavica.

[19]  M. Ceppi,et al.  Efficacy and Safety of Controlled Ovarian Stimulation With or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis , 2019, Frontiers in Oncology.

[20]  Wendy Y. Zhang,et al.  Maternal and neonatal outcomes associated with trophectoderm biopsy. , 2019, Fertility and sterility.

[21]  F. Clatot,et al.  Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy , 2019, Front. Oncol..

[22]  F. Broekmans,et al.  Growth, health, and motor development of 5-year-old children born after preimplantation genetic diagnosis. , 2019, Fertility and sterility.

[23]  M. Dolmans,et al.  Translational research aiming to improve survival of ovarian tissue transplants using adipose tissue‐derived stem cells , 2019, Acta obstetricia et gynecologica Scandinavica.

[24]  J. Litton,et al.  Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer , 2019, Current opinion in oncology.

[25]  S. Loibl,et al.  Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients. , 2019, Reproductive biomedicine online.

[26]  D. Choi,et al.  Association of BRCA Mutations and Anti-müllerian Hormone Level in Young Breast Cancer Patients , 2019, Front. Endocrinol..

[27]  Z. Rosenwaks,et al.  BRCA carriers have similar reproductive potential at baseline to noncarriers: comparisons in cancer and cancer-free cohorts undergoing fertility preservation. , 2019, Fertility and sterility.

[28]  E. Papanikolaou,et al.  BRCA1/2 gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to mature in vitro , 2019, Human reproduction.

[29]  Sandler,et al.  Breast Cancer Risk After Recent Childbirth , 2018, Annals of Internal Medicine.

[30]  Erlisa Bardhi,et al.  Fertility preservation in ovarian tumours , 2018, Ecancermedicalscience.

[31]  J. Forbes,et al.  Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. , 2018, Journal of the National Cancer Institute.

[32]  J. Hopper,et al.  The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations , 2018, JNCI cancer spectrum.

[33]  Fertility preservation and reproduction in patients facing gonadotoxic therapies: an Ethics Committee opinion. , 2018, Fertility and sterility.

[34]  M. Ceppi,et al.  Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  C. V. van Asperen,et al.  Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers , 2018, British Journal of Cancer.

[36]  K. Metcalfe,et al.  Uptake of Preimplantation Genetic Diagnosis in Female BRCA1 and BRCA2 Mutation Carriers , 2018, Journal of Genetic Counseling.

[37]  W. Foulkes,et al.  Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers , 2018, Breast Cancer Research and Treatment.

[38]  S. Loibl,et al.  Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  K. Oktay,et al.  Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  S. Loibl,et al.  The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. , 2018, Breast.

[41]  A. Tobar,et al.  Premature ovarian aging in BRCA carriers: a prototype of systemic precocious aging? , 2018, Oncotarget.

[42]  M. Candiani,et al.  Fertility preservation in women harboring deleterious BRCA mutations: ready for prime time? , 2018, Human reproduction.

[43]  G. Bedoschi,et al.  Ovarian Stimulation in Patients With Cancer: Impact of Letrozole and BRCA Mutations on Fertility Preservation Cycle Outcomes , 2018, Reproductive Sciences.

[44]  L. V. van Osch,et al.  Professionals' knowledge, attitude and referral behaviour of preimplantation genetic diagnosis for hereditary breast and ovarian cancer. , 2017, Reproductive biomedicine online.

[45]  Aung Ko Win,et al.  Reproductive factors as risk modifiers of breast cancer in BRCA mutation carriers and high-risk non-carriers , 2017, Oncotarget.

[46]  D. Adamson,et al.  GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  K. Oktay,et al.  Current Success and Efficiency of Autologous Ovarian Transplantation: A Meta-Analysis , 2017, Reproductive Sciences.

[48]  W. Chung,et al.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers , 2017, JAMA.

[49]  P. Scaruffi,et al.  State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature. , 2017, Cancer treatment reviews.

[50]  S. Domchek,et al.  Reproductive Decision-Making in Women with BRCA1/2 Mutations , 2017, Journal of Genetic Counseling.

[51]  S. Domchek,et al.  Antimüllerian hormone levels are lower in BRCA2 mutation carriers. , 2017, Fertility and sterility.

[52]  P. Humaidan,et al.  86 successful births and 9 ongoing pregnancies worldwide in women transplanted with frozen-thawed ovarian tissue: focus on birth and perinatal outcome in 40 of these children , 2017, Journal of Assisted Reproduction and Genetics.

[53]  W. Gradishar,et al.  Association of BRCA1 Mutations with Impaired Ovarian Reserve: Connection Between Infertility and Breast/Ovarian Cancer Risk. , 2016, Journal of adolescent and young adult oncology.

[54]  M. Eijkemans,et al.  Serum AMH levels in healthy women from BRCA1/2 mutated families: are they reduced? , 2016, Human reproduction.

[55]  O. Casasnovas,et al.  No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Sanjay Tanday.  IVF treatment not linked to breast cancer. , 2016, The Lancet. Oncology.

[57]  F. Cardoso,et al.  Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  M. Adank,et al.  Do BRCA1/2 mutation carriers have an earlier onset of natural menopause? , 2016, Menopause.

[59]  G. Bedoschi,et al.  Chemotherapy-induced damage to ovary: mechanisms and clinical impact. , 2016, Future oncology.

[60]  A. Thurin-Kjellberg,et al.  Ovarian tissue cryopreservation and transplantation among alternatives for fertility preservation in the Nordic countries – compilation of 20 years of multicenter experience , 2016, Acta obstetricia et gynecologica Scandinavica.

[61]  J. Hopper,et al.  Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations , 2016, Human reproduction.

[62]  A. Barros,et al.  Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect , 2016, The Lancet.

[63]  V. Turan,et al.  Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women With Breast Cancer. , 2016, The Journal of clinical endocrinology and metabolism.

[64]  L. Boni,et al.  Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial. , 2015, JAMA.

[65]  I. Chirivella,et al.  SEOM clinical guidelines in Hereditary Breast and ovarian cancer , 2015, Clinical and Translational Oncology.

[66]  E. Friedman,et al.  BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles. , 2015, Fertility and sterility.

[67]  A. Agarwal,et al.  Spermatogenesis, DNA damage and DNA repair mechanisms in male infertility. , 2015, Reproductive biomedicine online.

[68]  Marina Pollán,et al.  Mammographic density and breast cancer in women from high risk families , 2015, Breast Cancer Research.

[69]  R. Gelber,et al.  Pregnancy after breast cancer: Are young patients willing to participate in clinical studies? , 2015, Breast.

[70]  E. Friedman,et al.  Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers. , 2015, Fertility and sterility.

[71]  H. Skirton,et al.  The evidence base regarding the experiences of and attitudes to preimplantation genetic diagnosis in prospective parents. , 2015, Midwifery.

[72]  B. Karlan,et al.  BRCA1 germline mutations may be associated with reduced ovarian reserve. , 2014, Fertility and sterility.

[73]  T. Ludwig,et al.  Male Fertility Defect Associated with Disrupted BRCA1-PALB2 Interaction in Mice* , 2014, The Journal of Biological Chemistry.

[74]  W. Chung,et al.  Views of preimplantation genetic diagnosis among psychiatrists and neurologists. , 2014, The Journal of reproductive medicine.

[75]  Tomasz Żuradzki.  Preimplantation genetic diagnosis and rational choice under risk or uncertainty , 2014, Journal of Medical Ethics.

[76]  A. Paulussen,et al.  Hereditary breast and ovarian cancer and reproduction: an observational study on the suitability of preimplantation genetic diagnosis for both asymptomatic carriers and breast cancer survivors , 2014, Breast Cancer Research and Treatment.

[77]  E. Levy-Lahad,et al.  BRCA Mutation Carriers Do Not Have Compromised Ovarian Reserve , 2014, International Journal of Gynecologic Cancer.

[78]  C. Chapron,et al.  AMH concentration is not related to effective time to pregnancy in women who conceive naturally. , 2014, Reproductive biomedicine online.

[79]  J. Hopper,et al.  Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  B. Pothuri.  BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[81]  J. Lubiński,et al.  Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  O. Olopade,et al.  The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation , 2013, Breast Cancer Research and Treatment.

[83]  Lesley Smith,et al.  Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. , 2013, The Cochrane database of systematic reviews.

[84]  B. Karlan,et al.  Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. , 2013, Fertility and sterility.

[85]  S. Crawford,et al.  Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non–clinic‐based sample of women in northern California , 2013, Cancer.

[86]  R. Eeles,et al.  Reproductive decision-making in young female carriers of a BRCA mutation. , 2013, Human reproduction.

[87]  M. Robson,et al.  Impairment of BRCA1-Related DNA Double-Strand Break Repair Leads to Ovarian Aging in Mice and Humans , 2013, Science Translational Medicine.

[88]  Ken R. Smith,et al.  Effects of BRCA1 and BRCA2 mutations on female fertility , 2012, Proceedings of the Royal Society B: Biological Sciences.

[89]  W. Foulkes,et al.  Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers , 2012, Breast Cancer Research.

[90]  S. Vadaparampil,et al.  High-risk consumers’ perceptions of preimplantation genetic diagnosis for hereditary cancers: a systematic review and meta-analysis , 2011, Genetics in Medicine.

[91]  S. Vadaparampil,et al.  BRCA carriers' thoughts on risk management in relation to preimplantation genetic diagnosis and childbearing: when too many choices are just as difficult as none. , 2010, Fertility and sterility.

[92]  D. Keefe,et al.  Fertility in women with BRCA mutations: a case-control study. , 2010, Fertility and sterility.

[93]  T. Bonetti,et al.  Opinions concerning pre-implantation genetic diagnosis and sex selection among gynecologist-obstetricians in Brazil. , 2010, European journal of obstetrics, gynecology, and reproductive biology.

[94]  K. Oktay,et al.  Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  R. Moslehi,et al.  Impact of BRCA mutations on female fertility and offspring sex ratio , 2009, American journal of human biology : the official journal of the Human Biology Council.

[96]  C. Alonso,et al.  Opinion about reproductive decision making among individuals undergoing BRCA1/2 genetic testing in a multicentre Spanish cohort. , 2008, Human reproduction.

[97]  J. Liebelt,et al.  Preimplantation genetic diagnosis for BRCA1 exon 13 duplication mutation using linked polymorphic markers resulting in a live birth , 2008, Prenatal diagnosis.

[98]  I. Jacobs,et al.  Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer. , 2007, Human reproduction.

[99]  Irma H. Russo,et al.  The role of estrogen in the initiation of breast cancer , 2006, The Journal of Steroid Biochemistry and Molecular Biology.

[100]  O. Olopade,et al.  Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers , 2006, Breast Cancer Research.

[101]  Ivar Heuch,et al.  Clinical Stage of Breast Cancer by Parity, Age at Birth, and Time Since Birth: A Progressive Effect of Pregnancy Hormones? , 2006, Cancer Epidemiology Biomarkers & Prevention.

[102]  F. Couch,et al.  Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers , 2005, International journal of cancer.

[103]  M. Papa,et al.  Offspring gender ratio and the rate of recurrent spontaneous miscarriages in jewish women at high risk for breast/ovarian cancer. , 2004, American journal of human genetics.

[104]  B. Tarlatzis,et al.  Taskforce 5: preimplantation genetic diagnosis. , 2003, Human reproduction.

[105]  A. Partridge,et al.  Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application. , 2019, Cancer treatment reviews.

[106]  G. Giles,et al.  Breast Cancer Risk After Recent Childbirth : A Pooled Analysis of 15 Prospective Studies , 2019 .

[107]  M. Ignatiadis,et al.  Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[108]  H. Daum,et al.  BRCA mutations and reproduction. , 2018, Fertility and sterility.

[109]  E. Petridou,et al.  IVF and breast cancer: a systematic review and meta-analysis. , 2014, Human reproduction update.

[110]  Use of preimplantation genetic diagnosis for serious adult onset conditions: a committee opinion. , 2013, Fertility and sterility.

[111]  I. Smith,et al.  Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[112]  C. Finck,et al.  Knowledge and attitudes towards preimplantation genetic diagnosis in Germany. , 2005, Human reproduction.